Methods of using antibodies to block human thymic stromal lymphopoietin (TSLP) receptor activity
AssigneeAmgen Inc.
InventorsChris Saris, Ming-Shi Chang
Life of this patent
Estimating the term…
Abstract
The present invention provides Thymic Stromal Lymphopoietin Receptor (TSLPR) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TSLPR polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TSLPR polypeptides.
Claims6
A method of blocking human thymic stromal lymphopoietin (TSLP) receptor activity, said method comprising contacting a cell expressing human TSLP receptor with an effective amount of an antibody or antigen-binding fragment thereof that specifically binds the extracellular domain of the TSLP receptor having the amino acid sequence set forth in SEQ ID NO:6 and blocks human TSLP binding to the amino acid sequence.
Dependencies are inferred from the claim text.